Medical Devices; Neurological Devices; Classification of the Computerized Behavioral Therapy Device for the Treatment of Fibromyalgia Symptoms
FDA classifies computerized behavioral therapy device for fibromyalgia as a medical device, not a cosmetic. No direct impact on MoCRA-regulated cosmetics businesses.
Aforeworn detected this change in the Cosmetics & Personal-Care (MoCRA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Cosmetics and personal care businesses (indie brands, contract manufacturers, private-label makers, importers/distributors) regulated under MoCRA. should confirm how it applies to their specific situation before acting. There is a time constraint attached: N/A. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Cosmetics & Personal-Care (MoCRA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA issued a final classification order for a computerized behavioral therapy device for fibromyalgia symptoms, placing it under medical device regulations. This does not affect cosmetics or personal care products.
Who it affects
Cosmetics and personal care businesses (indie brands, contract manufacturers, private-label makers, importers/distributors) regulated under MoCRA.
What you must do
No action required for cosmetics businesses. Continue compliance with MoCRA requirements.
Deadline
N/A
Never miss a change like this again
Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Cosmetics & Personal-Care (MoCRA)
- FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
- FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
- FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
- FDA Expands AI Capabilities and Completes Data Platform Consolidation
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection